title: Phytoestrogens in menopausal supplements induce ER-dependent cell proliferation and overcome breast cancer treatment in an in vitro breast cancer model.
abstract: Breast cancer treatment by the aromatase inhibitor Letrozole (LET) or Selective Estrogen Receptor Modulator Tamoxifen (TAM) can result in the onset of menopausal symptoms. Women often try to relieve these symptoms by taking menopausal supplements containing high levels of phytoestrogens. However, little is known about the potential interaction between these supplements and breast cancer treatment, especially aromatase inhibitors. In this study, interaction of phytoestrogens with the estrogen receptor alpha and TAM action was determined in an ER-reporter gene assay (BG1Luc4E2 cells) and human breast epithelial tumor cells (MCF-7). Potential interactions with aromatase activity and LET were determined in human adrenocorticocarcinoma H295R cells. We also used the previously described H295R/MCF-7 co-culture model to study interactions with steroidogenesis and tumor cell proliferation. In this model, genistein (GEN), 8-prenylnaringenin (8PN) and four commercially available menopausal supplements all induced ER-dependent tumor cell proliferation, which could not be prevented by physiologically relevant LET and 4OH-TAM concentrations. Differences in relative effect potencies between the H295R/MCF-7 co-culture model and ER-activation in BG1Luc4E2 cells, were due to the effects of the phytoestrogens on steroidogenesis. All tested supplements and GEN induced aromatase activity, while 8PN was a strong aromatase inhibitor. Steroidogenic profiles upon GEN and 8PN exposure indicated a strong inhibitory effect on steroidogenesis in H295R cells and H295R/MCF-7 co-cultures. Based on our in vitro data we suggest that menopausal supplement intake during breast cancer treatment should better be avoided, at least until more certainty regarding the safety of supplemental use in breast cancer patients can be provided.
authors.affiliation: Endocrine Toxicology, Institute for Risk Assessment Sciences, Utrecht University, Yalelaan 104, Utrecht, The Netherlands. M.vanDuursen@uu.nl
authors.forename: Majorie B M
authors.initials: MB
authors.lastname: van Duursen
authors.forename: Evelien E J W
authors.initials: EE
authors.lastname: Smeets
authors.forename: Jeroen C W
authors.initials: JC
authors.lastname: Rijk
authors.forename: Sandra M
authors.initials: SM
authors.lastname: Nijmeijer
authors.forename: Martin
authors.initials: M
authors.lastname: van den Berg
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D019587:Dietary Supplements; D004305:Dose-Response Relationship, Drug; D004336:Drug Antagonism; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D008593:Menopause; D048789:Phytoestrogens / Q000494:pharmacology*; D011960:Receptors, Estrogen / Q000502:physiology*
chemical_list: D000970:Antineoplastic Agents; D048789:Phytoestrogens; D011960:Receptors, Estrogen